PSMA-PET Highlights Evolution of Molecular Imaging in Prostate Cancer
Andrei H. Iagaru, MD, discusses molecular imaging and the use of prostate-specific membrane antigen PET scans in prostate cancer and highlights other key presentations from the 2023 Prost8 Cancer Conference.
Combination Regimens May Expand PARP Inhibitor Efficacy in mCRPCFebruary 21st 2023
Tian Zhang, MD, MHS, discusses findings with single-agent PARP inhibitors within homologous recombination repair–deficient metastatic castration-resistant prostate cancer and describes how these advances pave the way for combining PARP inhibitors with hormonal therapies.
New Technology Advances Prostate Cancer Care But Questions LingerFebruary 21st 2023
Phillip J. Koo, MD, highlights insights garnered from prostate cancer experts on topics such as radioligands and modern radiopharmaceuticals, which, along with artificial intelligence, have the potential to revolutionize the field.
Multidisciplinary Discussions Move the Needle Toward Innovative Prostate Cancer CareFebruary 21st 2023
Michael S. Cookson, MD, MMHC, explains how discrepancies in defining biochemical recurrence are sparking a conversation about creating more consistent definitions that could allow for more widely applicable standards of care in prostate cancer .